TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33656542

Group type: EXPERIMENTAL
Intervention: Combined division of the splenic vein
Number of subjects: 316

Group type: COMPARATOR
Intervention: Separate division of the splenic vein
Number of subjects: 316
Study: 32908007

Group type: EXPERIMENTAL
Intervention: Topical application of Roseomonas mucosa
Number of subjects: 15
Study: 35987213

Group type: EXPERIMENTAL
Intervention: saccharin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: sucralose
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: aspartame
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: stevia
Number of subjects: 120

Group type: COMPARATOR
Intervention: vehicle glucose or no supplement
Number of subjects: 120
Study: 34331186

Group type: EXPERIMENTAL
Intervention: BMS (computer-assisted 3D measurement system)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PT (premeasured tape)
Number of subjects: 63

Group type: COMPARATOR
Intervention: VJ (visual judgment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: IM (instrument markings)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BMS
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PT
Number of subjects: 63

Group type: COMPARATOR
Intervention: VJ
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: IM
Number of subjects: 63
Study: 33399530

Group type: EXPERIMENTAL
Intervention: WeChat
Number of subjects: 70

Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 70
Study: 35817498

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study: 33872583

Group type: EXPERIMENTAL
Intervention: Choline bitartrate supplements (n = 20)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Hardboiled eggs (n = 18)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hardboiled eggs + choline bitartrate supplements (n = 16)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Egg whites + choline bitartrate supplements (n = 18)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Phosphatidylcholine supplements (n = 10)
Number of subjects: 82
Study: 32810220

Group type: EXPERIMENTAL
Intervention: Ofatumumab (1000 mg)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 438
Study: 36431201

Group type: EXPERIMENTAL
Intervention: Standardized punicalagin enriched oral pomegranate extract (Pomella®) daily for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 34053748

Group type: EXPERIMENTAL
Intervention: Oral regimen causing moderate nausea
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Monthly IV regimen causing mild memory problems
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Weekly IV regimen causing mild memory and mild neuropathy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Moderate neuropathy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 2-year PFS
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cost
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 6-month PFS
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Neuropathy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Memory problems
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Nausea
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Regimen
Number of subjects: 123
Study: 34667864

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-soaked gelfoam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Betamethasone-soaked gelfoam
Number of subjects: 100
Study: 36248820

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (NG)
Number of subjects: 40
Study: 32465484

Group type: EXPERIMENTAL
Intervention: TAPSE/sPAP (T/P)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: RV‐MPI
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: TRG
Number of subjects: 205
Study: 34437072

Group type: EXPERIMENTAL
Intervention: Unified Robust Semisupervised Variational Autoencoder Generative Adversarial Network (URSVAE-GAN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unified Robust Semisupervised Variational Autoencoder (URSVAE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denoising layer integrated into URSVAE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robust ?-divergence measure
Number of subjects: 0
Study: 32967068

Group type: EXPERIMENTAL
Intervention: Oral vitamin D (ergocalciferol) at 40,000 IU per week
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35964356

Group type: EXPERIMENTAL
Intervention: EXP (Stroop task)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CON (documentary)
Number of subjects: 20
Study: 32405570

Group type: EXPERIMENTAL
Intervention: High NO3− (140 ml of beetroot juice (BJ) per day, 800 mg of NO3−/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate NO3− (70 ml of BJ per day, 400 mg of NO3−/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low NO3− (70 ml on alternate days, 400 mg of NO3−)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NO3− depleted (70 ml on alternate days, 0.001 mg of NO3)
Number of subjects: 60
Study: 33639543

Group type: EXPERIMENTAL
Intervention: Heart-focused breathing protocol (10 minutes daily for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 10
Study: 32375661

Group type: EXPERIMENTAL
Intervention: Digital reminiscence therapy (digital RT), 8 sessions over 4 weeks.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional reminiscence therapy (storytelling, control group), 8 sessions over 4 weeks.
Number of subjects: 49
Study: 36050872

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Manuka mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pro-Dental mouthwash
Number of subjects: 45
Study: 32815384

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard physiotherapy treatment
Number of subjects: 80
Study: 35228288

Group type: EXPERIMENTAL
Intervention: PERFECT‐ER, an enhanced recovery pathway with 15 quality targets supported by a checklist and manual, a service improvement lead, a process lead, implemented using a plan‐do‐study‐act model.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard acute hospital care (control group).
Number of subjects: 284
Study: 34747925

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both Ivabradine and Bisoprolol
Number of subjects: 40
Study: 35867685

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 34183510

Group type: EXPERIMENTAL
Intervention: Non-antibiotic treatment (anti-inflammatory and symptomatic treatment)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Antibiotic treatment (875/125 mg/8 h amoxicillin/clavulanic acid)
Number of subjects: 480
Study: 32546645

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 615
Study: 34102933

Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Neglect
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Higher maternal level of education
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Daily screen time
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Emotionally maltreated and neglected participants
Number of subjects: 518
Study: 32928045

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 146

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 146
Study: 36244843

Group type: EXPERIMENTAL
Intervention: Straight chimney (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Angled chimney (Group II)
Number of subjects: 90
Study: 33627624

Group type: EXPERIMENTAL
Intervention: Active HD-tDCS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Active Conv-tDCS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 66
Study: 33357231

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TAM) for 2 years
Number of subjects: 564

Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: High (≥ 50%) infiltration of TILs
Number of subjects: 564
Study: 34937686

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 33370158

Group type: EXPERIMENTAL
Intervention: Violent video game
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 300
Study: 32736597

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg twice daily on day 1, followed by 200 mg twice daily on days 8, 15, and 22 for Group 1; 400 mg twice daily on day 1 followed by 200 mg twice daily for 5-7 days for Group 2)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 2300
Study: 35489301

Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 33863673

Group type: EXPERIMENTAL
Intervention: Nurses' experiences in managing early trauma emergencies
Number of subjects: 7
Study: 35960075

Group type: EXPERIMENTAL
Intervention: astragalus injection with chemotherapy regimen containing anthracycline epirubicin
Number of subjects: 248

Group type: COMPARATOR
Intervention: chemotherapy regimen containing anthracycline epirubicin
Number of subjects: 248
Study: 32658264

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 2463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2463

Group type: COMPARATOR
Intervention: Abaloparatide, Teriparatide, Placebo
Number of subjects: 2463
Study: 36333741

Group type: EXPERIMENTAL
Intervention: Flexible charrière‐4 feeding tube (group 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Semi‐rigid catheter (group 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study: 34496844

Group type: EXPERIMENTAL
Intervention: 3D printed models during the lecture
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control group (2D images only)
Number of subjects: 347
Study: 35238652

Group type: EXPERIMENTAL
Intervention: MuIS+
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Surgical limb (SX)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Contralateral limb (CTRL)
Number of subjects: 70
Study: 34029674

Group type: EXPERIMENTAL
Intervention: Foot reflexology massage for 15 min, for two consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 32789761

Group type: EXPERIMENTAL
Intervention: Non-dispensing clinical pharmacists integrated in primary care teams
Number of subjects: 388

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 388

Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 388
Study: 36116675

Group type: EXPERIMENTAL
Intervention: Gastric Conditioning (GC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Successful Gastric Conditioning (GC)
Number of subjects: 38
Study: 33297739

Group type: EXPERIMENTAL
Intervention: Threat condition (n=187)
Number of subjects: 309

Group type: COMPARATOR
Intervention: No-Threat condition (n=122)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: High compassion
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Low compassion
Number of subjects: 309
Study: 34394243

Group type: EXPERIMENTAL
Intervention: Home care based on the Neuman Systems Model
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 160
Study: 36106465

Group type: EXPERIMENTAL
Intervention: Heat acclimation training (5 consecutive days of moderate-intensity cycling at 60 min·day‐1 at 50% peak power output in a hot environment of 34.9±0.7 °C and 53±4 % relative humidity)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heat acclimation training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Temperate training environment (22.2±2.6 °C; 65±8 % relative humidity)
Number of subjects: 8
Study: 32889792

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine
Number of subjects: 106
Study: 32452973

Group type: EXPERIMENTAL
Intervention: FC2 Female Condom with a silicone placebo vaginal ring
Number of subjects: 81

Group type: COMPARATOR
Intervention: FC2 Female Condom without a silicone placebo vaginal ring
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Safety and tolerability assessment
Number of subjects: 81
Study: 35149205

Group type: EXPERIMENTAL
Intervention: AYUSH‐64 (two tablets of 500 mg each, three times a day for 30 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study: 35436944

Group type: EXPERIMENTAL
Intervention: Oil-based contrast during hysterosalpingography (HSG)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Water-based contrast during hysterosalpingography (HSG)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Oil-based contrast during HSG
Number of subjects: 930

Group type: COMPARATOR
Intervention: Water-based contrast during HSG
Number of subjects: 930
Study: 34195865

Group type: EXPERIMENTAL
Intervention: GLP1RA
Number of subjects: 948342

Group type: COMPARATOR
Intervention: DPP4i
Number of subjects: 948342
Study: 32074255

Group type: EXPERIMENTAL
Intervention: Antidepressant discontinuation
Number of subjects: 123
Study: 36169439

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser vitreolysis
Number of subjects: 8
Study: 32451788

Group type: EXPERIMENTAL
Intervention: Footprints (Motivational Interviewing-based prevention program)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment-as-usual waitlist control
Number of subjects: 43
Study: 36083097

Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening with a synthetic osmotic dilator
Number of subjects: 339

Group type: COMPARATOR
Intervention: Inpatient cervical ripening with a synthetic osmotic dilator
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening
Number of subjects: 339

Group type: COMPARATOR
Intervention: Inpatient cervical ripening
Number of subjects: 339
Study: 32378266

Group type: EXPERIMENTAL
Intervention: High-power (50 W) radiofrequency applications
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional-power (25-40 W) radiofrequency applications
Number of subjects: 120
Study: 36164014

Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB) 200 mg QD for 24 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Danazol (DAN) 600 mg QD for 24 weeks
Number of subjects: 100
Study: 33611104

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg daily (n = 261)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo (n = 131)
Number of subjects: 392
Study: 33350752

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no HCQ)
Number of subjects: 34
Study: 33595256

Group type: EXPERIMENTAL
Intervention: Foveal-sparing ILM peeling (FS group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Complete ILM peeling
Number of subjects: 34
Study: 32603994

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal instruction (EXP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control intervention (CON)
Number of subjects: 47
Study: 33567023

Group type: EXPERIMENTAL
Intervention: Microperimetry in fast mode (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microperimetry in expert mode (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microperimetry expert mode (fixation stability)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between macular sensitivity threshold and examination duration
Number of subjects: 30
Study: 32520644

Group type: EXPERIMENTAL
Intervention: 10 min neuromuscular training (INT10, n = 175)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 20 min neuromuscular training (INT20, n = 167)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 10 min neuromuscular training (INT10)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 20 min neuromuscular training (INT20)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 342
Study: 35246053

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and a tailored intervention (home visits by a nurse with a comprehensive fall risk assessment and a personalised intervention care plan, including six nurse home visits and five nurse phone calls).
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Usual care-control group (routine care for the prevention or treatment of diseases).
Number of subjects: 1190
Study: 33459247

Group type: EXPERIMENTAL
Intervention: Methyl Jasmonate (MJ) treatment at 30 mM
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Methyl Jasmonate (MJ) treatment at 60 mM
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Methyl Jasmonate (MJ) treatment at 100 mM
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (0 mM MJ)
Number of subjects: 3
Study: 32383636

Group type: EXPERIMENTAL
Intervention: Self-efficacy (measured on a 10-point Likert-type scale)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Knowledge (evaluated through 11 true/false items)
Number of subjects: 196
Study: 34606114

Group type: EXPERIMENTAL
Intervention: Two-dose group (tetravalent measles-mumps-rubella-varicella vaccine)
Number of subjects: 5803

Group type: EXPERIMENTAL
Intervention: One-dose group (monovalent varicella vaccine)
Number of subjects: 5803

Group type: COMPARATOR
Intervention: Control group (two doses of measles-mumps-rubella vaccine)
Number of subjects: 5803
Study: 33006001

Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS) monitoring, lymphoedema education and support
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS) monitoring
Number of subjects: 20
Study: 33872815

Group type: EXPERIMENTAL
Intervention: Follicular flushing (FF) using a 17-G double lumen needle
Number of subjects: 206

Group type: COMPARATOR
Intervention: Direct follicular aspiration using a 17-G single lumen needle
Number of subjects: 206
Study: 36346534

Group type: EXPERIMENTAL
Intervention: Safinamide (50 mg once daily, increased to 100 mg once daily at day 15)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Safinamide
Number of subjects: 307
Study: 32003644

Group type: EXPERIMENTAL
Intervention: Trigonal Botulinum toxin‐A (BTX‐A) injections (240 U into the detrusor plus 60 U into the trigone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontrigonal Botulinum toxin‐A (BTX‐A) injections (300 U into the detrusor sparing the trigone)
Number of subjects: 0
Study: 32293523

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 150 mg/day for 60 days
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 400 mg/day for 15 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Benznidazole (BNZ) 300 mg/day for 60 days (comparator arm)
Number of subjects: 240
Study: 35606139

Group type: EXPERIMENTAL
Intervention: Virtual community of practice (vCoP) intervention for 12 months
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study: 34776161

Group type: EXPERIMENTAL
Intervention: Individual pelvic floor exercises
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Individual pelvic floor exercises with ultrasonography guidance
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Group pelvic floor exercises
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 33
Study: 33181797

Group type: EXPERIMENTAL
Intervention: Swing shift (noon to midnight)
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: Weekend days
Number of subjects: 3532
Study: 32127659

Group type: EXPERIMENTAL
Intervention: Whole-genome/methylome prediction (WGMP) using Bayes-B model with SNPs selected based on LD-pruning and 1% of methylation sites based on Bayesian ridge regression (BRR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-genome prediction (WGP) using SNP marker information only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-methylome prediction (WMP) using methylation profiles only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayesian regression models studied: BRR, Bayes-A, Bayes-B, Bayes-C, Bayesian LASSO
Number of subjects: 0
Study: 35267997

Group type: EXPERIMENTAL
Intervention: Written dietary advice for lowering LDL cholesterol
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (triglycerides advice)
Number of subjects: 113
Study: 33252549

Group type: EXPERIMENTAL
Intervention: 30 tablets of hydrocodone/acetaminophen 10 to 325 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: 60 tablets of hydrocodone/acetaminophen 10 to 325 mg
Number of subjects: 111
Study: 36138306

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: COVID-19 patients (severe group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with thrombotic events
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: VWF in COVID-19 patients
Number of subjects: 106
Study: 33843675

Group type: EXPERIMENTAL
Intervention: Blue-green (500 nm) light therapy for SCD treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Blue-green (500 nm) light therapy for aMCI treatment
Number of subjects: 150
Study: 35181275

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) intervention integrated in electronic health records, activated for patients with elevated cholesterol levels.
Number of subjects: 500000

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 500000